Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary 
Medicus Pharma CEO charts course for 2025 with clinical milestones for SkinJect
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX), a biotechnology company specializing in non-invasive dermatological treatments, is gearing up for a pivotal year in 2025. The company is advancing SkinJect, its flagship asset for basal cell carcinoma, while planning significant expansions to its drug pipeline.
Medicus Pharma achieves FDA MUMS approval for equine squamous cell carcinoma patch - ICYMI
Earlier this week Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that its innovative skin patch treatment has received Minor Use and Minor Species (MUMS) designation from the FDA. The patch, which uses a cellulose-based, doxorubicin-loaded design, is aimed at treating squamous cell carcinoma in horses.
Medicus Pharma's horse skin cancer treatment wins MUMS designation from FDA
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that the Food and Drug Administration has granted Minor Use in Major Species (MUMS) designation for its Investigational New Animal Drug, a dissolvable Doxorubicin-containing microneedle array (D-MNA) patch targeting external squamous cell carcinoma in horses. The MUMS designation, akin to the Orphan Drug status for human medicine, provides Medicus with a seven-year exclusive marketing period following product approval or conditional approval, contingent on meeting the program's requirements.
Medicus Pharma CEO on basal-cell carcinoma trial progress – ICYMI
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) provided an update on its phase two clinical trial for a novel non-invasive treatment targeting basal-cell carcinoma. CEO Raza Bokhari told Proactive that 25% of patient recruitment for the U.S.-based trial has been completed.
Medicus Pharma eyes pivotal trial for novel skin cancer therapy as Phase 2 enrollment progresses
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced that its Phase 2 clinical study targeting basal cell carcinoma (BCC) is now being conducted at nine clinical sites across the United States, with more than 25% of the 60 patients expected to be enrolled in the study already randomized. An interim data analysis is planned for Q1 2025, and Medicus intends to submit these findings to the US Food and Drug Administration (FDA) to request a Type C meeting in Q2 2025, the company said on Monday.
Medicus Pharma partners with Swanielle to expand basal cell carcinoma study into Asia-Pacific
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced it has entered into an agreement with healthcare consulting firm Swanielle to explore expanding its Phase 2 clinical study for treating Basal Cell Carcinoma (BCC) into the Asia-Pacific region. The collaboration aims to identify potential pharmaceutical or biotech partners in Southeast Asia to facilitate this expansion.
Medicus Pharma announces pricing of US IPO
Medicus Pharma (TSX-V:MDCX) announced the pricing of its US initial public offering (IPO), with 970,000 units priced at $4.125 per unit. Each unit will comprise one common share and one warrant, which are exercisable at $4.64 and have a five-year expiry.
